Ting-Ting Zhao1, Hao Xu2, Hui-Mian Xu3, Zhen-Ning Wang3, Ying-Ying Xu1, Yong-Xi Song3, Song-Cheng Yin3, Xing-Yu Liu3, Zhi-Feng Miao4. 1. Department of Breast Surgery, First Hospital of China Medical University, Shenyang, Liaoning, China. 2. Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. 3. Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, Liaoning, China. 4. Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, Liaoning, China. zfmiao@cmu.edu.cn.
Abstract
BACKGROUND: Advanced gastric cancer (AGC) is a severe malignant tumor associated with high mortality. Targeted therapy is an important approach for improving the therapeutic effects of AGC treatment. This study evaluates the efficacy and safety of targeted agents for AGC patients. METHODS: PubMed, EmBase, and the Cochrane Library were searched for double-blind randomized controlled trials (RCTs) of AGC treatments published prior to July 2017. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and severe adverse effects (AEs) were evaluated to determine the efficacy and safety of targeted agents. A network meta-analysis with a frequentist framework was performed to assess the effects of various targeted agents for AGC treatment. RESULTS: Our analysis included 16 articles involving 5371 patients and 11 types of agents. The network meta-analysis showed that apatinib (97.5%) was most likely to improve PFS, followed by regorafenib (86.3%) and rilotumumab (65.4%). Apatinib was similarly best for OS outcome, (95.5%) followed by rilotumumab (74.7%) and regorafenib (70%). Apatinib (89.6%) also had the best improvement on ORR, followed by rilotumumab (75.4%) and everolimus (68.4%). Bevacizumab (85.5%) was likely to get the lowest severe AEs, followed by sunitinib (63%). CONCLUSIONS: Apatinib, regorafenib, and rilotumumab improved patient PFS and OS. When combined with chemotherapy, ramucirumab and rilotumumab had high efficacy but low tolerability, and bevacizumab had moderate efficacy and tolerability for PFS. Without chemotherapy, ramucirumab and regorafenib had relatively high therapeutic efficacy tolerability for PFS.
BACKGROUND: Advanced gastric cancer (AGC) is a severe malignant tumor associated with high mortality. Targeted therapy is an important approach for improving the therapeutic effects of AGC treatment. This study evaluates the efficacy and safety of targeted agents for AGC patients. METHODS: PubMed, EmBase, and the Cochrane Library were searched for double-blind randomized controlled trials (RCTs) of AGC treatments published prior to July 2017. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and severe adverse effects (AEs) were evaluated to determine the efficacy and safety of targeted agents. A network meta-analysis with a frequentist framework was performed to assess the effects of various targeted agents for AGC treatment. RESULTS: Our analysis included 16 articles involving 5371 patients and 11 types of agents. The network meta-analysis showed that apatinib (97.5%) was most likely to improve PFS, followed by regorafenib (86.3%) and rilotumumab (65.4%). Apatinib was similarly best for OS outcome, (95.5%) followed by rilotumumab (74.7%) and regorafenib (70%). Apatinib (89.6%) also had the best improvement on ORR, followed by rilotumumab (75.4%) and everolimus (68.4%). Bevacizumab (85.5%) was likely to get the lowest severe AEs, followed by sunitinib (63%). CONCLUSIONS:Apatinib, regorafenib, and rilotumumab improved patient PFS and OS. When combined with chemotherapy, ramucirumab and rilotumumab had high efficacy but low tolerability, and bevacizumab had moderate efficacy and tolerability for PFS. Without chemotherapy, ramucirumab and regorafenib had relatively high therapeutic efficacy tolerability for PFS.
Authors: Nick Pavlakis; Katrin M Sjoquist; Andrew J Martin; Eric Tsobanis; Sonia Yip; Yoon-Koo Kang; Yung-Jue Bang; Thierry Alcindor; Christopher J O'Callaghan; Margot J Burnell; Niall C Tebbutt; Sun Young Rha; Jeeyun Lee; Jae-Yong Cho; Lara R Lipton; Mark Wong; Andrew Strickland; Jin Won Kim; John R Zalcberg; John Simes; David Goldstein Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero Journal: Lancet Date: 2013-10-03 Impact factor: 79.321
Authors: Giuseppe Aprile; Riccardo Giampieri; Marta Bonotto; Alessandro Bittoni; Elena Ongaro; Giovanni Gerardo Cardellino; Francesco Graziano; Francesco Giuliani; Gianpiero Fasola; Stefano Cascinu; Mario Scartozzi Journal: Expert Opin Investig Drugs Date: 2014-05-07 Impact factor: 6.206
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: H H Yoon; J C Bendell; F S Braiteh; I Firdaus; P A Philip; A L Cohn; N Lewis; D M Anderson; E Arrowsmith; J D Schwartz; L Gao; Y Hsu; Y Xu; D Ferry; S R Alberts; Z A Wainberg Journal: Ann Oncol Date: 2016-10-20 Impact factor: 51.769
Authors: João Q Coentro; Andrea De Pieri; Diana Gaspar; Dimitrios Tsiapalis; Dimitrios I Zeugolis; Yves Bayon Journal: J Mater Sci Mater Med Date: 2019-12-02 Impact factor: 3.896
Authors: M Santero; J Pérez-Bracchiglione; R Acosta-Dighero; A G Meade; A Antequera; A Auladell-Rispau; M J Quintana; C Requeijo; G Rodríguez-Grijalva; K Salas-Gama; R Dorantes-Romandia; J Salazar; I Solà; G Urrútia; X Bonfill Cosp Journal: BMC Cancer Date: 2021-06-16 Impact factor: 4.430